StockMacro
Menu

Edesa Biotech

$2.00 -79% in 6 monthsMarket cap $19.3M

EDSA on XNAS, Health Care, Edesa Biotech, Inc., job postings

Measures activity, not value. Not investment advice.

Stock is down 81% in six months while cash of $10.3M sits against a $14.1M annual loss.

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Jun 2026

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Industry
Pharmaceutical preparations (Health Care)
Employees
17
Website
edesabiotech.com
Listed
Nasdaq, US
Last results
13 Aug 2026
Next results
expected around 11 Dec 2026 (an estimate: a year ago it reported on 12 Dec 2025)
Revenue and net income per quarter. Quarter to 30 Jun 2026: net loss $5.4M.
Quarter to 31 Dec 2021: revenue –, net income -$4.4MQuarter to 31 Mar 2022: revenue –, net income -$4.6MQuarter to 30 Jun 2022: revenue –, net income -$5.8MQuarter to 30 Sep 2022: revenue –, net income -$2.8MQuarter to 31 Dec 2022: revenue –, net income -$2.3MQuarter to 31 Mar 2023: revenue –, net income -$2.3MQuarter to 30 Jun 2023: revenue –, net income -$2.0MQuarter to 30 Sep 2023: revenue –, net income -$1.7MQuarter to 31 Dec 2023: revenue –, net income -$1.7MQuarter to 31 Mar 2024: revenue –, net income -$1.9MQuarter to 30 Jun 2024: revenue –, net income -$1.7MQuarter to 30 Sep 2024: revenue –, net income -$962KQuarter to 31 Dec 2024: revenue –, net income -$1.6MQuarter to 31 Mar 2025: revenue –, net income -$1.6MQuarter to 30 Jun 2025: revenue –, net income -$1.7MQuarter to 30 Sep 2025: revenue –, net income -$2.2MQuarter to 31 Dec 2025: revenue –, net income -$2.2MQuarter to 31 Mar 2026: revenue –, net income -$4.2MQuarter to 30 Jun 2026: revenue –, net income -$5.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $5.8M30 Jun 2026
See the numbers
Quarter toRevenueNet income
30 Jun 2026–-$5.4M
31 Mar 2026–-$4.2M
31 Dec 2025–-$2.2M
30 Sep 2025–-$2.2M
30 Jun 2025–-$1.7M
31 Mar 2025–-$1.6M
31 Dec 2024–-$1.6M
30 Sep 2024–-$962K
30 Jun 2024–-$1.7M
31 Mar 2024–-$1.9M
31 Dec 2023–-$1.7M
30 Sep 2023–-$1.7M
30 Jun 2023–-$2.0M
31 Mar 2023–-$2.3M
31 Dec 2022–-$2.3M
30 Sep 2022–-$2.8M
30 Jun 2022–-$5.8M
31 Mar 2022–-$4.6M
31 Dec 2021–-$4.4M
Fundamentals, 12 months to 30 Jun 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$14.1M -$5.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -123% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $10.3M $12.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$10.3M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.91
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.0

Latest = 12 months to 30 Jun 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Edesa BiotechEDSA (this company) $19.3Mloss–––
IGC PharmaIGC $19.6Mloss15.6+14%-644%
China PharmaCPHI $18.9Mloss4.4+6.4%-133%
TherapeuticsMDTXMD $19.8M1625.3+34%3.3%
Adicet BioACET $20.0Mloss–––
TransCode TherapeuticsRNAZ $20.1Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

0%

34 13F filers vs 34

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

76%

7.3M shares held by 13F filers (30 Sep 2026) of 9.6M outstanding (13 Aug 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.6%

158K shares sold short (30 Oct 2026) of 9.6M outstanding (13 Aug 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.0

158K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-2.0%

161K shares sold short in the report before, 158K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

38%

38% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 40%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

0

0 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

0 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $2.00 on 20 Nov 2026, +16% over 12 months (12-month range $0.80 to $18.27)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $233K in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 34 13F filers reported holding it in the latest 13F quarter, +55% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Nov 20268-K and other filingsA major agreement ended
23 Oct 20268-K and other filingsDirector or officer change
23 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jun 20268-K and other filingsPrivate placement of securities (Form D)
29 May 20268-K and other filingsDirector or officer change
15 May 20268-K and other filingsDirector or officer change
15 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2026Sharp changeShort interest spike: short interest spike, 514K vs usual 26K (2026-04-30); 12.5x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 603K vs usual 26K (2026-03-13); 6.2x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 1.4M vs usual 26K (2026-02-27); 13.2x the same period a year earlier
28 May 20258-K and other filingsDirector or officer change
4 Apr 20258-K and other filingsDirector or officer change
4 Mar 2025Sharp changeShort interest spike: short interest spike, 852K vs usual 17K (2025-02-14); 56.1x the same period a year earlier
14 Feb 20258-K and other filingsPrivate placement of securities (Form D)
13 Feb 20258-K and other filingsDirector or officer change
13 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 20248-K and other filingsA major agreement ended
4 Oct 20248-K and other filingsA major agreement ended
30 May 20248-K and other filingsDirector or officer change
30 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Jun 20238-K and other filingsDirector or officer change
23 Jun 20238-K and other filingsDelisting notice or listing transfer
24 May 20238-K and other filingsDirector or officer change
24 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Apr 2023Sharp changeShort interest spike: short interest spike, 906K vs usual 150K (2023-03-31); 6.8x the same period a year earlier
28 Mar 2023Sharp changeShort interest spike: short interest spike, 817K vs usual 150K (2023-03-15); 3.5x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 685K vs usual 150K (2023-02-28); 2.5x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 644K vs usual 150K (2023-02-15); 2.2x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 782K vs usual 150K (2023-01-31); 2.4x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 670K vs usual 150K (2023-01-13); 2.3x the same period a year earlier
17 Jan 2023Sharp changeShort interest spike: short interest spike, 815K vs usual 150K (2022-12-30); 3.0x the same period a year earlier
11 Apr 20228-K and other filingsRegistered new securities for sale (S-1)
5 Apr 20228-K and other filingsPrivate placement of securities (Form D)
29 Mar 20228-K and other filingsDirector or officer change
23 Mar 20228-K and other filingsA major agreement ended
4 Mar 20228-K and other filingsDirector or officer change
2 Mar 20228-K and other filingsDirector or officer change
2 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: $62K published
Month from 1 Apr 2022: $12K published
Month from 1 May 2022: $10K published
Month from 1 Jun 2022: $14K published
Month from 1 Jul 2022: $36K published
Month from 1 Jan 2023: -$787K published
Month from 1 Mar 2024: $20K published
Month from 1 Mar 2026: $233K published
Revenue per quarter
Quarter ended 30 Sep 2021: $0; public on 29 Dec 2021
Capital spending per quarter
Quarter ended 31 Dec 2021: $3K, +177% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $1K, -60% on a year earlier; public on 14 May 2022
Quarter ended 30 Jun 2022: $1K, -61% on a year earlier; public on 13 Aug 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 11 Feb 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $0; public on 16 Dec 2023
Institutional holders (13F filers)
31 Dec 2021 report: 22; public on 14 Feb 2022
31 Mar 2022 report: 20; public on 16 May 2022
30 Jun 2022 report: 21; public on 15 Aug 2022
30 Sep 2022 report: 18; public on 14 Nov 2022
31 Dec 2022 report: 20; public on 14 Feb 2023
31 Mar 2023 report: 24; public on 15 May 2023
30 Jun 2023 report: 19; public on 14 Aug 2023
30 Sep 2023 report: 17; public on 14 Nov 2023
31 Dec 2023 report: 18; public on 14 Feb 2024
31 Mar 2024 report: 17; public on 15 May 2024
30 Jun 2024 report: 17; public on 14 Aug 2024
30 Sep 2024 report: 17; public on 14 Nov 2024
31 Dec 2024 report: 15; public on 14 Feb 2025
31 Mar 2025 report: 19; public on 15 May 2025
30 Jun 2025 report: 17; public on 14 Aug 2025
30 Sep 2025 report: 22; public on 14 Nov 2025
31 Dec 2025 report: 22; public on 17 Feb 2026
31 Mar 2026 report: 28; public on 15 May 2026
30 Jun 2026 report: 34; public on 14 Aug 2026
30 Sep 2026 report: 34; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is net income, quarter at -$5.4M (30 Jun 2026), 212% below its normal quarter of -$1.7M; higher than 6% of its own history.
  • Insider net buying (open market): Insiders bought a net $233K in the last 12 months (the 12 months before: $0).
  • Revenue per quarter: Revenue $0 in the latest quarter.
  • Capital spending per quarter: Capital spending $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 45 insider trades

No trades in the last 90 days; the latest was filed 11 Mar 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
11 Mar 2026Michael J BrooksPresidentBuy2,000$1.57$3KForm 4
10 Mar 2026Pardeep NijhawanChief Executive OfficerBuy1,000$6.60$7KForm 4
6 Mar 2026Pardeep NijhawanChief Executive OfficerBuy10,000$3.90$39KForm 4
5 Mar 2026Pardeep NijhawanChief Executive OfficerBuy10,000$4.26$43KForm 4
4 Mar 2026Pardeep NijhawanChief Executive OfficerBuy10,000$3.63$36KForm 4
3 Mar 2026Pardeep NijhawanChief Executive OfficerBuy3,000$2.09$6KForm 4
2 Mar 2026Pardeep NijhawanChief Executive OfficerBuy50,571$1.96$99KForm 4
25 Mar 2024Pardeep Nijhawan and 1 otherChief Executive OfficerBuy5,000$4.00$20KForm 4

34 institutions reported shares at the end of Q3 2026, 76% of the shares outstanding; 5 opened a position, 6 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Velan Capital Investment Management LP1.3M13.3%$5.4M+455K+55%
Millennium Management LLC1.2M12.2%$5.0M+617K+110%
Boxer Capital Management, LLC937K9.72%$3.9M+732K+357%
Stempoint Capital LP825K8.56%$3.5MNew+825K
Stonepine Capital Management, LLC710K7.37%$3.0M+254K+56%
Rubric Capital Management LP622K6.45%$2.6M-47K-7.1%
Perceptive Advisors LLC563K5.84%$2.4MNo change
Adage Capital Partners GP, L.L.C.550K5.70%$2.3MNew+550K
Heights Capital Management, Inc204K2.11%$858KNew+204K
Vanguard Capital Management LLC82K0.85%$345KNo change

Company events

All 68 company events

In 12 months: 3 director or officer changes, 3 major agreements, 1 private placement, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Nov 2026Granted Kyorin Pharmaceutical Co., Ltd. exclusive Japan license to paridiprubart for ARDS; $12M upfront, up to $55M development milestones; A major agreement ended8-K
23 Oct 2026Director or officer change8-K
20 Aug 2026Signed a major agreement8-K
26 Jun 2026Private placement of securities (Form D)$3.5M sold of $3.5M offeredD
11 Jun 2026Signed a major agreementSame filing: sold shares privately8-K
29 May 2026Director or officer changeSame filing: shareholder vote results8-K
15 May 2026Director or officer change8-K
30 Sep 2025Signed a major agreementSame filing: took on new debt8-K
Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 9 Nov 2026Filings record

    A major agreement ended

  2. 23 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 23 Oct 2026Filings record

    Director or officer change

  4. 26 Jun 2026Filings record

    Private placement of securities (Form D)

  5. 29 May 2026Filings record

    Director or officer change

  6. 15 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 15 May 2026Filings record

    Director or officer change

  8. 12 May 2026Short interest and volume change

    had 514K shares sold short in the 30 Apr 2026 report, 13× the same report last year.

    Same report last year: 41K; its normal report is 26K.

    See the evidence
    This period
    514K (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    26K
    Typical spread (median absolute deviation)
    18K
    How far from its usual level
    +9.7
    Same report last year
    41K
    History used
    2,512 days
    2025-04-30: 41K2025-05-15: 22K2025-05-30: 14K2025-06-13: 29K2025-06-30: 25K2025-07-15: 16K2025-07-31: 6,4052025-08-15: 7,0892025-08-29: 8,4102025-09-15: 6,9022025-09-30: 6,9812025-10-15: 9,3282025-10-31: 128K2025-11-14: 57K2025-11-28: 51K2025-12-15: 35K2025-12-31: 28K2026-01-15: 14K2026-01-30: 28K2026-02-13: 15K2026-02-27: 1.4M2026-03-13: 603K2026-03-31: 397K2026-04-15: 268K2026-04-30: 514K
    the 30 Apr 2026 report24 earlier reportsnormal: 26K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 25 Mar 2026Short interest and volume change

    had 603K shares sold short in the 13 Mar 2026 report, 6.2× the same report last year.

    Same report last year: 97K; its normal report is 26K.

    See the evidence
    This period
    603K (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    26K
    Typical spread (median absolute deviation)
    18K
    How far from its usual level
    +11.5
    Same report last year
    97K
    History used
    2,464 days
    2025-03-14: 97K2025-03-31: 73K2025-04-15: 55K2025-04-30: 41K2025-05-15: 22K2025-05-30: 14K2025-06-13: 29K2025-06-30: 25K2025-07-15: 16K2025-07-31: 6,4052025-08-15: 7,0892025-08-29: 8,4102025-09-15: 6,9022025-09-30: 6,9812025-10-15: 9,3282025-10-31: 128K2025-11-14: 57K2025-11-28: 51K2025-12-15: 35K2025-12-31: 28K2026-01-15: 14K2026-01-30: 28K2026-02-13: 15K2026-02-27: 1.4M2026-03-13: 603K
    the 13 Mar 2026 report24 earlier reportsnormal: 26K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 12 Mar 2026Insiders record

    Brooks Michael J (President) bought 2,000 shares of EDSA ($3,140) (dated 11 Mar 2026)

  11. 11 Mar 2026Short interest and volume change

    had 1.4M shares sold short in the 27 Feb 2026 report, 13× the same report last year.

    Same report last year: 107K; its normal report is 26K.

    See the evidence
    This period
    1.4M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    26K
    Typical spread (median absolute deviation)
    18K
    How far from its usual level
    +27.7
    Same report last year
    107K
    History used
    2,450 days
    2025-02-28: 107K2025-03-14: 97K2025-03-31: 73K2025-04-15: 55K2025-04-30: 41K2025-05-15: 22K2025-05-30: 14K2025-06-13: 29K2025-06-30: 25K2025-07-15: 16K2025-07-31: 6,4052025-08-15: 7,0892025-08-29: 8,4102025-09-15: 6,9022025-09-30: 6,9812025-10-15: 9,3282025-10-31: 128K2025-11-14: 57K2025-11-28: 51K2025-12-15: 35K2025-12-31: 28K2026-01-15: 14K2026-01-30: 28K2026-02-13: 15K2026-02-27: 1.4M
    the 27 Feb 2026 report24 earlier reportsnormal: 26K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 11 Mar 2026Insiders record

    Nijhawan Pardeep (Chief Executive Officer) bought 1,000 shares of EDSA ($6,600) (dated 10 Mar 2026)

  13. 7 Mar 2026Insiders record

    Nijhawan Pardeep (Chief Executive Officer) bought 10,000 shares of EDSA ($39,000) (dated 6 Mar 2026)

  14. 6 Mar 2026Insiders record

    Nijhawan Pardeep (Chief Executive Officer) bought 10,000 shares of EDSA ($42,600) (dated 5 Mar 2026)

  15. 5 Mar 2026Insiders record

    Nijhawan Pardeep (Chief Executive Officer) bought 10,000 shares of EDSA ($36,300) (dated 4 Mar 2026)

  16. 4 Mar 2026Insiders record

    Nijhawan Pardeep (Chief Executive Officer) bought 3,000 shares of EDSA ($6,280) (dated 3 Mar 2026)

  17. 3 Mar 2026Insiders record

    Nijhawan Pardeep (Chief Executive Officer) bought 50,571 shares of EDSA ($99,102) (dated 2 Mar 2026)

  18. 28 May 2025Filings record

    Director or officer change

  19. 4 Apr 2025Filings record

    Director or officer change

  20. 27 Feb 2025Short interest and volume change

    had 852K shares sold short in the 14 Feb 2025 report, 56× the same report last year.

    Same report last year: 15K; its normal report is 17K.

    See the evidence
    This period
    852K (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    1,582
    How far from its usual level
    +16.7
    Same report last year
    15K
    History used
    2,072 days
    2024-02-15: 15K2024-02-29: 17K2024-03-15: 18K2024-03-28: 19K2024-04-15: 15K2024-04-30: 16K2024-05-15: 11K2024-05-31: 15K2024-06-14: 16K2024-06-28: 18K2024-07-15: 18K2024-07-31: 18K2024-08-15: 16K2024-08-30: 15K2024-09-13: 17K2024-09-30: 13K2024-10-15: 20K2024-10-31: 17K2024-11-15: 48K2024-11-29: 35K2024-12-13: 21K2024-12-31: 5,4762025-01-15: 4,7282025-01-31: 17K2025-02-14: 852K
    the 14 Feb 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 14 Feb 2025Filings record

    Private placement of securities (Form D)

  22. 13 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 13 Feb 2025Filings record

    Director or officer change

  24. 31 Oct 2024Filings record

    A major agreement ended

  25. 4 Oct 2024Filings record

    A major agreement ended

  26. 30 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 30 May 2024Filings record

    Director or officer change

  28. 26 Mar 2024Insiders record

    Nijhawan Pardeep (Chief Executive Officer) and 1 other(s) bought 5,000 shares of EDSA ($20,000) (dated 25 Mar 2024)

  29. 27 Jun 2023Filings record

    Director or officer change

  30. 23 Jun 2023Filings record

    Delisting notice or listing transfer

  31. 24 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 24 May 2023Filings record

    Director or officer change

  33. 13 Apr 2023Short interest and volume change

    had 906K shares sold short in the 31 Mar 2023 report, 6.8× the same report last year.

    Same report last year: 134K; its normal report is 150K.

    See the evidence
    This period
    906K (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    116K
    How far from its usual level
    +4.4
    Same report last year
    134K
    History used
    1,386 days
    2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K2023-01-13: 670K2023-01-31: 782K2023-02-15: 644K2023-02-28: 685K2023-03-15: 817K2023-03-31: 906K
    the 31 Mar 2023 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 25 Mar 2023Short interest and volume change

    had 817K shares sold short in the 15 Mar 2023 report, 3.5× the same report last year.

    Same report last year: 233K; its normal report is 150K.

    See the evidence
    This period
    817K (the 15 Mar 2023 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    93K
    How far from its usual level
    +4.8
    Same report last year
    233K
    History used
    1,370 days
    2022-03-15: 233K2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K2023-01-13: 670K2023-01-31: 782K2023-02-15: 644K2023-02-28: 685K2023-03-15: 817K
    the 15 Mar 2023 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 10 Mar 2023Short interest and volume change

    had 685K shares sold short in the 28 Feb 2023 report, 2.5× the same report last year.

    Same report last year: 271K; its normal report is 150K.

    See the evidence
    This period
    685K (the 28 Feb 2023 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    93K
    How far from its usual level
    +3.9
    Same report last year
    271K
    History used
    1,355 days
    2022-02-28: 271K2022-03-15: 233K2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K2023-01-13: 670K2023-01-31: 782K2023-02-15: 644K2023-02-28: 685K
    the 28 Feb 2023 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 28 Feb 2023Short interest and volume change

    had 644K shares sold short in the 15 Feb 2023 report, 2.2× the same report last year.

    Same report last year: 296K; its normal report is 150K.

    See the evidence
    This period
    644K (the 15 Feb 2023 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    93K
    How far from its usual level
    +3.6
    Same report last year
    296K
    History used
    1,342 days
    2022-02-15: 296K2022-02-28: 271K2022-03-15: 233K2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K2023-01-13: 670K2023-01-31: 782K2023-02-15: 644K
    the 15 Feb 2023 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 10 Feb 2023Short interest and volume change

    had 782K shares sold short in the 31 Jan 2023 report, 2.4× the same report last year.

    Same report last year: 323K; its normal report is 150K.

    See the evidence
    This period
    782K (the 31 Jan 2023 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    93K
    How far from its usual level
    +4.6
    Same report last year
    323K
    History used
    1,327 days
    2022-01-31: 323K2022-02-15: 296K2022-02-28: 271K2022-03-15: 233K2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K2023-01-13: 670K2023-01-31: 782K
    the 31 Jan 2023 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 26 Jan 2023Short interest and volume change

    had 670K shares sold short in the 13 Jan 2023 report, 2.3× the same report last year.

    Same report last year: 297K; its normal report is 150K.

    See the evidence
    This period
    670K (the 13 Jan 2023 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    93K
    How far from its usual level
    +3.8
    Same report last year
    297K
    History used
    1,309 days
    2022-01-14: 297K2022-01-31: 323K2022-02-15: 296K2022-02-28: 271K2022-03-15: 233K2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K2023-01-13: 670K
    the 13 Jan 2023 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 12 Jan 2023Short interest and volume change

    had 815K shares sold short in the 30 Dec 2022 report, 3.0× the same report last year.

    Same report last year: 270K; its normal report is 150K.

    See the evidence
    This period
    815K (the 30 Dec 2022 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    93K
    How far from its usual level
    +4.8
    Same report last year
    270K
    History used
    1,295 days
    2021-12-15: 270K2022-01-14: 297K2022-01-31: 323K2022-02-15: 296K2022-02-28: 271K2022-03-15: 233K2022-03-31: 134K2022-04-14: 152K2022-04-29: 149K2022-05-13: 129K2022-05-31: 105K2022-06-15: 118K2022-06-30: 87K2022-07-15: 67K2022-07-29: 63K2022-08-15: 17K2022-08-31: 96K2022-09-15: 84K2022-09-30: 52K2022-10-14: 302K2022-10-31: 334K2022-11-15: 355K2022-11-30: 370K2022-12-15: 386K2022-12-30: 815K
    the 30 Dec 2022 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 6 Jul 2022Insiders record

    Pardeep Nijhawan Medicine Professional Corp (Chief Executive Officer) and 1 other(s) bought 20,000 shares of EDSA ($32,000) (dated 5 Jul 2022)

Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.

Not listed: 160 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001540159
Ticker
EDSA
Domain
edesabiotech.com
Hq location
|TORONTO|M5H 2 (1 unverified)
Name
Edesa Biotech, Inc., Stellar Biotechnologies, Inc.
  • SEC Form 13F institutional holdings270 data points30 Jun 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)195 records20 Jan 2016 to 17 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)731 data points31 Aug 2011 to 13 Aug 2026
  • SEC Form 4 insider transactions45 records, 156 data points14 Mar 2018 to 11 Mar 2026
  • FINRA short interest (twice monthly)531 data points14 Jun 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3744 data points10 Jun 2019 to 20 Nov 2026